Purple Biotech Ltd. (PPBT)
| Market Cap | 78.47M |
| Revenue (ttm) | 1,000,000 |
| Net Income (ttm) | -5.89M |
| Shares Out | 1.94M |
| EPS (ttm) | -3.00 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 22 |
| Last Price | $4.61 |
| Previous Close | $4.65 |
| Change ($) | -0.04 |
| Change (%) | -0.86% |
| Day's Open | 4.70 |
| Day's Range | 4.54 - 4.70 |
| Day's Volume | 241,297 |
| 52-Week Range | 0.23 - 4.94 |
REHOVOT, Israel, Jan. 18, 2021 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. (“Purple Biotech”) (NASDAQ/TASE: PPBT), a clinical-stage company advancing first-in-class therapies to overcome tumor imm...
Virtual Bell-Ringing Ceremony in Celebration of Company's Recent Name Change to Purple Biotech
New Name Reflects Company's Evolution to Advancing First-in-Class Oncology Therapies
TEL AVIV, Israel, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasio...
The new cohort will explore the combination of CM24, Opdivo (“nivolumab”) and Abraxane (“albumin-bound paclitaxel; nab-paclitaxel”) in patients with pancreatic cancer The new cohort will explo...
Patent covers NT219's combinations with multiple 2nd and 3rd generation EGFR inhibitors, including osimertinib (TAGRISSO®)
Data Further Support Potential of NT219 to Overcome Cancer Drug Resistance
Top Line Results from First Part of the Study Expected in Second Half of 2021 Top Line Results from First Part of the Study Expected in Second Half of 2021
Kitov’s patent coverage for CM24 and NT219 now extends to the U.S., EU, China, and multiple ROW countries
TEL AVIV, Israel, Aug. 12, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evas...
TEL AVIV, Israel, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evas...
Is (KTOV) Outperforming Other Medical Stocks This Year?
Company Evaluating NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for the Treatment of Recurrent and/or Metastatic Solid Tumors and Head and Neck Cancer
Patent coverage for CM24 now extends to the U.S. and the EU
Ties With Merck Could Explain Kitov's Market Interest
TEL AVIV, July 02, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and dr...
TEL-AVIV, Israel, June 25, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evas...
TEL-AVIV, Israel, June 23, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evas...
Company to Evaluate NT219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with Cetuximab for Treatment of Recurrent or Metastatic Solid Tumors and Head and Neck Cancer in ...
TEL AVIV, Israel, May 20, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evas...
Company Expects to Initiate Phase 1/2 Trial of NT-219 as Monotherapy Treatment of Advanced Solid Tumors and in Combination with cetuximab for Treatment of Recurrent or Metastatic Solid Tumors ...
Company Expects to Initiate Phase 1/2 Clinical trial, in Collaboration with Bristol Myers Squibb, with CM-24 in Combination with nivolumab (Opdivo®) in Second Half of 2020
Tufin Software Technologies Ltd. (TUFN) CEO Ruvi Kitov on Q1 2020 Results - Earnings Call Transcript
Tufin Software Technologies Ltd. (TUFN) CEO Ruvi Kitov on Q1 2020 Results - Earnings Call Transcript
TEL-AVIV, Israel, May 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasi...
TEL-AVIV, Israel, April 20, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune ev...
TEL AVIV, Israel, March 12, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune ev...
Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, today announced it will expan...
Tufin Software Technologies' (TUFN) CEO Ruvi Kitov on Q4 2019 Results - Earnings Call Transcript
Patent Provides Coverage Until 2035 and Strengthens Company’s IP Portfolio
TEL AVIV, Israel, Jan. 24, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evas...
TEL AVIV, Israel, Jan. 09, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evas...
TEL AVIV, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune eva...
TEL AVIV, Israel, Jan. 08, 2020 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evas...
Kitov Pharma recently updated their Consensi commercial agreement with Coeptis Pharmaceuticals. I review the original and updated agreement and provide my thoughts on the amendments.
TEL AVIV, Israel, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evas...
TEL AVIV, Israel, Oct. 02, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune e...
Kitov Pharma presented encouraging NT-219 data that confirmed its mechanism of action in reversing drug resistance in mouse models. The company is planning on submitting an IND before year-end.
Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, presented newly released proo...
Tufin Software Technologies Ltd. (TUFN) CEO Ruvi Kitov on Q2 2019 Results - Earnings Call Transcript
Tufin Software Technologies Ltd. (TUFN) CEO Ruvi Kitov on Q2 2019 Results - Earnings Call Transcript
TEL AVIV, Israel, Sept. 03, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune eva...
TEL AVIV, Israel, Aug. 29, 2019 (GLOBE NEWSWIRE) -- Kitov Pharma Ltd. (“Kitov”) (NASDAQ/TASE: KTOV), a clinical-stage company advancing first-in-class therapies to overcome tumor immune e...
Kitov Pharma's Consensi is close to launching and will mark the company's transition into a commercial-stage company. However, the stock trades under $1 and is at risk for delisting.
Kitov is in the final stages of acquiring FameWave and their promising oncology agent CM-24. This acquisition now makes a Kitov an oncology-focused company.
About PPBT
Purple Biotech, a clinical-stage pharmaceutical company, focuses on the development and commercialization of various pharmaceutical drugs. It operates through two segments, Oncology, and Pain and Hypertension. The company's marketed products include Consensi, a fixed-dose combination of celecoxib and amlodipine besylate for the simultaneous treatment of osteoarthritis pain and hypertension in the United States, as well as in China and South Korea. Its oncology pipeline includes NT-219, a small molecule that is advancing as a monotherapy treatme... [Read more...]
| Industry Biotechnology | Founded 2010 |
| CEO Itzhak Israel | Employees 9 |
| Stock Exchange NASDAQ | Ticker Symbol PPBT |
Financial Performance
In 2019, Purple Biotech's revenue was $1,000,000, a change of 0.00% compared to the previous year's $1,000,000. Losses were -$5.89 million, 5.82% more than in 2018.